Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Breast Cancer

Topics

Medicine

Cancer Oncology

Internal Medicine

Cancer Research

Triple-Negative Breast Cancer

Show all topics

DOI

10.1007/s12282-024-01657-4